Arixtra solution for injection 2.5 mg/0.5 ml syringe No. 10

Arixtra injection solution is indicated for:

Composition

Active ingredient: fondaparinux sodium;

1 syringe (0.5 ml) contains 2.5 mg of fondaparinux sodium;

Excipients: sodium chloride, water for injection, hydrochloric acid or sodium hydroxide.

Contraindication

Known allergy to the active substance or to any of the excipients of the drug. Active clinically significant bleeding. Acute bacterial endocarditis. Severe renal failure (creatinine clearance <20 ml/min).

Method of application

Arixtra is for subcutaneous or intravenous injection. Do not administer intramuscularly. Arixtra is for use only under the supervision of a physician.

Application features

Pregnant women

Not recommended for use.

Drivers

With caution.

Overdose

Exceeding the recommended doses of the drug may lead to an increased risk of bleeding. There is no known antidote to fondaparinux.

In case of overdose accompanied by hemorrhagic complications, treatment should be discontinued and the underlying cause of bleeding should be investigated. Appropriate therapy, such as surgical hemostasis, blood replacement, fresh plasma transfusion, plasmapheresis, should be considered.

Side effects

The most frequently reported serious adverse reactions with fondaparinux are haemorrhagic complications (at various sites, including isolated cases of intracranial/intracerebral and retroperitoneal haemorrhage) and anaemia. Fondaparinux should be used with caution in patients at increased risk of bleeding.

Interaction

Drugs that increase the risk of bleeding should not be used concomitantly with Arixtra, with the exception of vitamin K antagonists used to treat venous thromboembolism. If such co-administration is necessary, it should be carried out under close supervision.

Storage conditions

Store below 25°C.

Keep out of reach of children.

Shelf life - 3 years.